KetoSwiss
A Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
N/A | Seed | ||
| Total Funding | 000k | ||
| EUR | 2018 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Company filings or news article
Related Content
KetoSwiss AG, a privately held biotechnology company headquartered in Basel, Switzerland, was incorporated in December 2017. The company was founded by Dr. Elena Gross, who serves as the CEO, Dr. Marco Cerf, and Dr. Michelle L.A. Teo. Dr. Gross's journey into this field began with her own experience with migraines, leading her to investigate the potential of ketone bodies for migraine prevention during her PhD in neuroscience at the University of Basel. This personal and scientific exploration forms the foundation of KetoSwiss's mission.
The company is focused on developing therapeutics for neurological diseases linked to metabolic dysfunctions, with an initial emphasis on migraine prevention. KetoSwiss operates in the nutraceutical and medical food market, targeting individuals who suffer from high-frequency migraines. Its business model centers on the development and clinical testing of its lead product, a medical food designed to offer a dietary therapy. The core of this product is a ketone body, an endogenous metabolite that the brain can use as an alternative energy source to glucose. This is particularly relevant for conditions where glucose utilization might be impaired.
KetoSwiss's primary product is a powder that can be mixed with water, formulated to induce a state of ketosis without requiring a strict ketogenic diet. This product, sometimes referred to as MigraKet, aims to address the energy deficit in the brains of migraine sufferers by providing an alternative fuel. The company's approach is grounded in clinical validation, with a proof-of-concept study completed in 2021 showing promising results in migraine reduction. KetoSwiss has secured funding through various means, including a significant seed financing round and non-dilutive funding from Innosuisse, the Swiss Innovation Agency, to support its clinical trials and product development.
Keywords: biotechnology, migraine prevention, neurological diseases, medical food, nutraceuticals, ketone bodies, metabolic dysfunction, Basel, clinical trials, neuroscience